2005 Share Price Performance
Recent 2005 News & Updates
No updates
SSY Group Limited Key Details
Last Reported Earnings
Dec 31, 2024
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- 0.36
- Gross Margin
- 50.37%
- Net Profit Margin
- 18.38%
- Debt/Equity Ratio
- 48.2%
SSY Group Limited Competitors
About 2005
- Founded
- 1999
- Employees
- 6146
- CEO
- WebsiteView website
SSY Group Limited, an investment holding company, researches, develops, manufactures, trades in, and sells various pharmaceutical products to hospitals and distributors in the People’s Republic of China and internationally. The company offers intravenous infusion solutions, including non-PVC and upright soft bag, PP plastic bottle, and glass bottle infusion solutions, as well as ampoule injections. It also provides small volume injections, oral preparations, Chinese medicine preparations, and biological preparations, as well as bulk pharmaceutical products and medical materials. In addition, the company is involved in the research, development, and consulting of pharmaceutical technology; provision of logistics services for pharmaceutical products; food, beverages, and catering businesses; and production and sale of methylamine. It sells its products under the Shimen brand name. The company was formerly known as Lijun International Pharmaceutical (Holding) Co., Ltd. and changed its name to SSY Group Limited in May 2015. The company was founded in 1999 and is headquartered in Wan Chai, Hong Kong.
Hong Kong Market Performance
- 7 Days: -3.1%
- 3 Months: 13.4%
- 1 Year: 38.8%
- Year to Date: 25.5%
Over the last 7 days, the market has dropped 3.1%, driven by a pullback of 3.3% in the Financials sector. As for the longer term, the market has actually risen by 39% in the last year. Earnings are forecast to grow by 11% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading